Score an editor-approved summer dress for $15, plus 10 more of today's best sales
Even those of us who love our jobs sometimes need a little pick-me-up to get through the end of the week. The weekend's so close, yet so far! You know what always works for me? A little retail therapy. Sure, as a commerce writer, I might be biased, but I'm not talking about any old shopping. I'm talking about deals shopping, because few things can turn a frown upside down like saving money. That's why I've been on the lookout for fabulous on-sale finds, and, reader, there are some really good ones today. From one Yahoo editor's favorite warm-weather dress (marked down to $15!) to Apple AirPods for a record-low price, these are my top picks.
Adidas: Get up to 70% off sale shoes and apparel.
Anthropologie: Save up to 50% on sale items.
Brooklinen: Score bedding, bath linens and more for up to 75% off.
Coach Outlet: Save up to 70% on sale styles.
Cozy Earth: Get up to 30% off Oprah-approved bedding and pajamas during the Mother's Day Sale.
Everlane: Snag up to 80% off sale styles.
J.Crew: Save up to 50% more on already marked-down items.
Kate Spade Outlet: Get up to 70% off everything, plus an extra 20% off select styles.
Loft: Take 40% off your purchase.
Nordstrom: Shop new sale items for up to 65% off.
Nordstrom Rack: Save up to 75% on thousands of new deals.
Old Navy: Score 50% off hundreds of kid and baby items, plus tops starting at $6.
REI: Get up to 70% off camping supplies, running gear and past-season deals.
Spanx: Get up to 40% off select AirEssentials sale items, and up to 70% off sale items.
Sur La Table: Save up to 60% on top brands like Staub, Le Creuset and more.
Target: Get up to 50% off outdoor furniture, clothing and more.
Walmart: Shop rollbacks and flash deals of up to 80% off.
Wayfair: Stock up on furniture, linens and more for up to 60% off during the Bedroom Sale.
The reviews quoted above reflect the most recent versions at the time of publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Jobs report lift, Tesla stock rebounds, Lululemon sinks
Yahoo Finance host Madison Mills tracks today's top moving stocks and biggest market stories in this Market Minute, including Tesla's (TSLA) rebound this morning after erasing $153 billion in market value due to CEO Elon Musk's feud with President Trump and Lululemon Athletica (LULU) cutting its full-year forecast over tariff pressures. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. Time for Yahoo! Finance's market minute. Stocks are jumping, the S&P 500 breaking above the 6,000 level for the first time since February on the back of that stronger than expected May jobs report. President Trump taking a Truth Social to celebrate the data and call for the Fed to cut rates saying, quote, "Go for a full point." Plus, Tesla is rebounding from Thursday's slump as investors hope for a cooldown in the feud between Trump and CEO Elon Musk. The the online dust-up initially leading to a more than $150 billion wipeout of Tesla's value. And Lululemon shares sinking after the retailer cut its full year profit guidance citing higher tariff-related costs as well as increased markdowns. Number of analysts slashing their price targets on the stock while maintaining their ratings including BMO Capital, Needham and TD Cowen. That's your Yahoo! Finance market minute. For more on what's trending on Yahoo! Finance, you can scan the QR code below to track the best and worst performing stocks of this session. Connectez-vous pour accéder à votre portefeuille
Yahoo
4 hours ago
- Yahoo
TrusTrace's playbook aims to boost data, supply chain compliance
Titled "The Data Advantage – A Practical Guide to Building De-risked, Compliant and Future-Ready Supply Chains", the TrusTrace playbook launches at the Global Fashion Summit in Copenhagen. The playbook arrives at a time when the industry faces increased regulatory pressure, climate risks, and a demand for transparency that has led to a substantial reporting workload for suppliers. It introduces 'The TrusTrace Compliance Canvas', a framework aimed at aiding brands and manufacturers to better collaborate on a standardised set of supply chain data. This is backed by contributions from industry participants. Interviews with brands such as adidas, Hugo Boss, and Primark are featured within the playbook. These brands, along with suppliers like Epic Group, Karacasu Tekstil, and Impetus Group, discuss their strategies for data management and traceability in light of changing regulations and environmental objectives amidst policy uncertainty. Primark Product Traceability and Assurance head Cari Atkinson said: 'At Primark, we've focused on creating clarity for our suppliers by aligning on the data that matters most, and building the internal systems and skills to use it well. Working with TrusTrace has helped us turn complex data requirements into something more manageable for our teams and suppliers.' adidas Sustainability and ESG SVP Sigrid Buehrle said: 'My North Star is to get supply chain-related data to the same robustness as financial data. That's where we need to get to, with an effective data landscape and a standardised approach to data collection and evaluation.' The playbook also includes insights from Policy Hub on potential future policies, Textile ETP's views on global manufacturing preparedness, and an analysis of corporate climate litigation from The London School of Economics Grantham Research Institute on Climate Change and the Environment. The playbook underscores the importance of pragmatic collaboration in supply chain data management. It suggests that this data should be more than a compliance tool; it can also be instrumental in informed sourcing decisions and risk management. 'A fascinating insight from these interviews is that despite the already huge data burden, with myriad tools and many platforms and certifications, what's collected is mostly documents, not meaningful data or numbers for calculating and addressing actual environmental impacts. It's mere foundational due diligence,' the book's author Brooke Roberts-Islam stated. Brands and suppliers have also highlighted that subjective interpretations of regulations and inconsistent methodologies hinder achieving tangible outcomes, notes TrusTrace. TrusTrace CEO and co-founder Shameek Ghosh added: 'As data becomes the new cornerstone of compliance and climate readiness, brands need more than intention—they need infrastructure. This playbook outlines what actionable, standardised data collaboration should look like.' Last month, TrusTrace introduced an AI-powered enhancement to help fashion brands and manufacturers gather, centralise, and scrutinise supply chain traceability information. "TrusTrace's playbook aims to boost data, supply chain compliance" was originally created and published by Just Style, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL. In a recent Q&A hosted by Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, a patient advocacy group, Dr. Kim shared her gratitude to clinical trial participants and emphasized the urgent need for safer, more effective therapies for CTCL. The conversation underscored the progress being made with HyBryte™, Soligenix's novel, non-mutagenic photodynamic therapy. 'We need new therapies and access to therapies [for patients],' said Dr. Kim, noting that CTCL is a chronic disease which means that therapies with possible side effects, such as the development of contact dermatitis, sun damage or skin cancer from phototherapy, can become a real issue for patients over time. 'There hasn't been an FDA-approved, new skin-directed therapy for over 10 years, so we really need new ones that are safe and hopefully safer [than the ones currently in use].' Clinical results from ongoing studies have been promising, with Dr. Kim noting that participants have experienced positive outcomes and that the therapy has been well tolerated, with no dropouts due to serious adverse events. "HyBryte™ has a unique mechanism of action, so it doesn't damage DNA, unlike phototherapy, so theoretically it's less mutagenic and there's less risk of skin cancer. It's not systemically absorbed, based on prior studies, and seems to be quite well tolerated in terms of its effects on the local skin area,' added Dr. Kim. As a professor of dermatology at the Hospital of the University of Pennsylvania and Director of the Penn Cutaneous Lymphoma Program, Dr. Kim is keen to continue her research into CTCL with colleagues and patients alike. 'There aren't that many clinical trials going on for early-stage disease,' Dr. Kim stated, adding she is very excited for what lies ahead now that open enrollment in HyBryte™ clinical trials is available. 'Hopefully we can get this over the finish line. We can't thank patients enough; it's so critical for getting new therapies approved.' To watch Dr. Kim's interview and learn more about the real-world clinical study of the treatment of Mycosis Fungoides with Synthetic Hypericin and Visible Light, please visit: About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer (SGX942), and in Behçet's Disease (SGX945). Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA). For further information regarding Soligenix, Inc., please visit the Company's website at and follow us on LinkedIn and Twitter at @Soligenix_Inc. This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma or any other studies (including the open-label, investigator-initiated study), there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Additionally, despite the biologic activity observed in aphthous ulcers induced by chemotherapy and radiation, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. Corporate Communications IBN Austin, Texas 512.354.7000 Office Editor@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
